IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
View Patent ↗The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.
1. A method for treating a malignant tumor or blood cancer, in a subject suffering from such tumor or cancer, comprising administering a therapeutically effective dose of an ERK inhibitor, to the subject, wherein the ERK inhibitor is represented by a structural formula selected from the group consisting of:
wherein IL-8 levels, in the blood or serum of the subject are determined before and after said administration; and, administering one or more further doses of the ERK inhibitor if the IL-8 levels decrease from the time said IL-8 levels are determined before said administration to the time said IL-8 levels are determined after said administration.
2. The method of claim 1 wherein the tumor or blood cancer is a member selected from the group consisting of: lung cancer, lung adenocarcinoma, non small cell lung cancer, pancreatic cancer, pancreatic carcinoma, exocrine pancreatic carcinoma, colon cancer, colorectal carcinoma, colon adenocarcinoma, colon adenoma, myeloid leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, thyroid cancer, myelodysplastic syndrome, bladder carcinoma, epidermal carcinoma, melanoma, breast cancer, prostate cancer, head and neck cancer, squamous cell cancer of the head and neck, ovarian cancer, brain cancer, glioma, glioma blastoma multiforme, cancer of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma, sarcoma, tetracarcinomas, neuroblastoma, kidney carcinoma, hepatoma, non-Hodgkin's lymphoma, multiple myeloma, and anaplastic thyroid carcinoma.
3. The method of claim 1 wherein the subject is administered a further chemotherapeutic agent.
4. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
5. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
6. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
7. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
8. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
9. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
10. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
11. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
12. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
13. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
14. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
15. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
16. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
17. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
18. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
19. The method of claim 1 for treating a malignant tumor which is melanoma.
20. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
21. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
22. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
23. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula
24. The method of claim 1 wherein the ERK inhibitor is represented by the structural formula